BiotechTube
Home/BioMarin Pharmaceutical/Marni Kottle
MK

Marni Kottle

Executive Vice President, Chief Corporate Affairs & Patient Advocacy Officer

BioMarin Pharmaceutical

Therapeutic Areas

Rare Genetic DiseasesLysosomal Storage Disorders

BioMarin Pharmaceutical Pipeline

DrugIndicationPhase
VOXZOGO (vosoritide)AchondroplasiaApproved/Marketed
ROCTAVIAN (valoctocogene roxaparvovec)Severe Hemophilia AApproved/Marketed
PALYNZIQ (pegvaliase-pqpz)Phenylketonuria (PKU)Approved/Marketed
BMN 331 (giroctocogene fitelparvovec)Severe Hemophilia BPhase 1/2
BMN 349Genetic CardiomyopathyPreclinical
BMN 355Undisclosed Genetic CNS DisorderPreclinical

Leadership Team at BioMarin Pharmaceutical

AH
Alexander Hardy
President and Chief Executive Officer
BR
Brian R. Mueller
Executive Vice President, Chief Financial Officer
GF
Greg Friberg
Executive Vice President, Chief Research & Development Officer
CH
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
CG
C. Greg Guyer
Executive Vice President, Chief Technical Officer
JS
James Sabry
Executive Vice President, Chief Business Officer
AW
Amy Wireman
Executive Vice President, Chief People Officer
GE
G. Eric Davis
Executive Vice President, Chief Legal Officer
AD
Arpit Davé
Executive Vice President, Chief Digital and Information Officer
RA
Richard A. Meier
Chairman of the Board
View full BioMarin Pharmaceutical profile